<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01799694</url>
  </required_header>
  <id_info>
    <org_study_id>FLPURO-2009-01</org_study_id>
    <secondary_id>2009-016298-14</secondary_id>
    <nct_id>NCT01799694</nct_id>
  </id_info>
  <brief_title>Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO)</brief_title>
  <acronym>FLPURO</acronym>
  <official_title>Phase II Clinical Trial to Study the Feasibility and Safety of the Expanded Autologous Stem Cells Use Derived From Adipose Tissue (e-ASC) for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility and security of the autologous e-ASC
      for the urinary incontinence after a radical prostate cancer surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the feasibility and security of the autologous e-ASC for the urinary incontinence after a radical prostate cancer surgery</measure>
    <time_frame>16 weeks</time_frame>
    <description>Possibility of inject ASc by cystoscope</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment using the SF-12 Questionnaire</measure>
    <time_frame>1, 4, 16, 24 weeks</time_frame>
    <description>SF-12 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1, 4, 16, 24 weeks</time_frame>
    <description>Data collected</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Autologous Expanded Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject of Autologous Adipose-derived expanded stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inject of Autologous Adipose-derived stem cells</intervention_name>
    <description>Inject in muscle of autologous adipose derived stem cells</description>
    <arm_group_label>Autologous Expanded Stem Cells</arm_group_label>
    <other_name>Autologuos eASC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Men over 18 years old. Good general state of health according to the findings of the
             clinical history and the physical examination

          3. Prostate cancer diagnosed subjects via a biopsy and having had a radical surgery with
             a healing purpose in the previous 18 months

          4. Having urinary incontinence after the surgery

          5. Failure in any previous conservative treatment

        Exclusion Criteria:

          1. Having had an adjuvant treatment

          2. Having a PSA ≥ 0,2 after surgery

          3. Having any sign or symptom that suggest the investigator the non-healing of the
             adenocarcinoma

          4. Active urine infection

          5. Alcohol or other addictive substances abuse antecedents in the previous 6 months to
             the inclusion

          6. Cardiopulmonary illness that, in the investigator opinion, could be unstable or could
             be serious enough to drop the patient from the study

          7. Any kind of medical or psychiatric illness that, in the investigator opinion, could be
             a reason to exclude the patient from the study

          8. Subjects with congenital or acquired immunodeficiencies, B and/or C Hepatitis,
             Tuberculose or Treponema diagnosed at the moment of inclusion

          9. Anesthetic allergy

         10. Major surgery or severe trauma in the previous 6 months

         11. Administration of any drug under experimentation in the present or in the previous 3
             months before recruitment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Alonso Gregorio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cell Therapy laboratory and general Surgery Department, Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Strasser H, Tiefenthaler M, Steinlechner M, Eder I, Bartsch G, Konwalinka G. Age dependent apoptosis and loss of rhabdosphincter cells. J Urol. 2000 Nov;164(5):1781-5.</citation>
    <PMID>11025769</PMID>
  </reference>
  <reference>
    <citation>Andriole GL, Grubb III LB, Buys SS et als. for the PLCO Project Team</citation>
  </reference>
  <reference>
    <citation>Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.</citation>
    <PMID>19297566</PMID>
  </reference>
  <reference>
    <citation>Mitterberger M, Pinggera GM, Marksteiner R, Margreiter E, Plattner R, Klima G, Strasser H. Functional and histological changes after myoblast injections in the porcine rhabdosphincter. Eur Urol. 2007 Dec;52(6):1736-43. Epub 2007 May 22. Erratum in: Eur Urol. 2008 Nov;54(5):1208. Bartsch, Georg [removed].</citation>
    <PMID>17532554</PMID>
  </reference>
  <reference>
    <citation>Kwon D, Kim Y, Pruchnic R, Jankowski R, Usiene I, de Miguel F, Huard J, Chancellor MB. Periurethral cellular injection: comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. Urology. 2006 Aug;68(2):449-54.</citation>
    <PMID>16904482</PMID>
  </reference>
  <reference>
    <citation>Cannon TW, Lee JY, Somogyi G, Pruchnic R, Smith CP, Huard J, Chancellor MB. Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology. 2003 Nov;62(5):958-63.</citation>
    <PMID>14624934</PMID>
  </reference>
  <reference>
    <citation>Praud C, Sebe P, Biérinx AS, Sebille A. Improvement of urethral sphincter deficiency in female rats following autologous skeletal muscle myoblasts grafting. Cell Transplant. 2007;16(7):741-9.</citation>
    <PMID>18019363</PMID>
  </reference>
  <reference>
    <citation>Becker C, Jakse G. Stem cells for regeneration of urological structures. Eur Urol. 2007 May;51(5):1217-28. Epub 2007 Jan 18. Review.</citation>
    <PMID>17254699</PMID>
  </reference>
  <reference>
    <citation>Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001 Apr;7(2):211-28.</citation>
    <PMID>11304456</PMID>
  </reference>
  <reference>
    <citation>Kajbafzadeh AM, Elmi A, Payabvash S, Salmasi AH, Saeedi P, Mohamadkhani A, Sadeghi Z, Nikfarjam L. Transurethral autologous myoblast injection for treatment of urinary incontinence in children with classic bladder exstrophy. J Urol. 2008 Sep;180(3):1098-105. doi: 10.1016/j.juro.2008.05.057. Epub 2008 Jul 18.</citation>
    <PMID>18639289</PMID>
  </reference>
  <reference>
    <citation>Carr LK, Steele D, Steele S, Wagner D, Pruchnic R, Jankowski R, Erickson J, Huard J, Chancellor MB. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jun;19(6):881-3. doi: 10.1007/s00192-007-0553-z.</citation>
    <PMID>18204978</PMID>
  </reference>
  <reference>
    <citation>Mitterberger M, Marksteiner R, Margreiter E, Pinggera GM, Frauscher F, Ulmer H, Fussenegger M, Bartsch G, Strasser H. Myoblast and fibroblast therapy for post-prostatectomy urinary incontinence: 1-year followup of 63 patients. J Urol. 2008 Jan;179(1):226-31. Epub 2007 Nov 14.</citation>
    <PMID>18001790</PMID>
  </reference>
  <reference>
    <citation>Mitterberger M, Pinggera GM, Marksteiner R, Margreiter E, Fussenegger M, Frauscher F, Ulmer H, Hering S, Bartsch G, Strasser H. Adult stem cell therapy of female stress urinary incontinence. Eur Urol. 2008 Jan;53(1):169-75. Epub 2007 Jul 23.</citation>
    <PMID>17683852</PMID>
  </reference>
  <reference>
    <citation>García Olmo D, García-Verdugo JM, Alemany J, Gonzalez M, Gutierrez-Fuentes JA. CELL THERAPHY . Ed. Mac Graw Hill. Madrid 2007</citation>
  </reference>
  <reference>
    <citation>García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, García-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003 Sep;18(5):451-4. Epub 2003 May 20.</citation>
    <PMID>12756590</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.</citation>
    <PMID>19273960</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary incontinence</keyword>
  <keyword>Autologous expanded stem cells</keyword>
  <keyword>Radical prostate cancer surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

